1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Apixaban 2.5 MG: new trials by email Literature Review of Apixaban 2.5 MG trials Research Report on Apixaban 2.5 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs Apixaban 2.5 MG - Venous Thromboembolism | Phase 2 | Terminated | Instituto de Investigacion Sanitaria La Fe | 60 | 2019-04-12 | 2021-02-15 |
| A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg - VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery | Phase 2 | Completed | Janssen Research & Development, LLC | 308 | 2017-11-13 | 2019-11-25 |
Multiple Myeloma (1) · Venous Thromboembolism (1)
Instituto de Investigacion Sanitaria La Fe (1) · Janssen Research & Development, LLC (1)
Spain (2) · Argentina (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Italy (1) · Japan (1) · Latvia (1) · Lithuania (1) · Malaysia (1) · Poland (1) · Russia (1) · Turkey (Türkiye) (1) · Ukraine (1)
Javier de la Rubia (1) · Samuel Romero (1)
2016 (1)